Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
September 15, 2022 08:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
July 27, 2022 08:15 ET
|
Silo Pharma, Inc.
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma,...
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
July 12, 2022 11:23 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive...
Silo Pharma Expands License Agreement and Patent Portfolio
June 23, 2022 08:05 ET
|
Silo Pharma, Inc.
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June ...
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study
May 19, 2022 08:11 ET
|
Silo Pharma, Inc.
Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical...
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
April 20, 2022 08:10 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
March 31, 2022 08:10 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
February 03, 2022 08:22 ET
|
Silo Pharma, Inc.
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a...
Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange
December 14, 2021 08:07 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced...
Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
December 02, 2021 08:10 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the...